Physician profile
Anthony J Dangelo
NPI 1215938550
$1,602.29
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $243 · 2021: $298 · 2022: $270 · 2023: $198 · 2024: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $263.94 | 2019-2023 | Scopis Ent |
| Optinose US, INC. | $214.69 | 2019-2024 | |
| Abbvie INC. | $207.70 | 2022-2024 | |
| Novo Nordisk INC | $198.72 | 2020-2021 | |
| Intersect Ent, INC. | $164.96 | 2020-2021 | |
| Genzyme Corporation | $144.11 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $125.27 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $122.57 | 2020-2023 | |
| Checkpoint Surgical, INC | $31.66 | 2022 | |
| Acclarent, INC | $26.71 | 2019 | |
| Glaxosmithkline, LLC. | $22.93 | 2023 | Nucala |
| Nevro Corp. | $19.42 | 2023 | Senza |
| Kaleo, INC. | $17.49 | 2019 | |
| Hikma Pharmaceuticals USA | $14.54 | 2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $13.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Dangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.